News UK grants patients early access to AbbVie/Roche leukaemia dr... Venetoclax still under review in Europe.
Clinical AbbVie/Roche's Venclexta produces complete remission in 10% ... AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
Views & Analysis Obstacles to true patient centricity in Europe Campaigner and cancer patient Andrew Schorr says pharma needs to knock down the barriers to greater patient influence.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face